Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Drug Resistance

Free Subscription Articles published in AIDS Retrieve available abstracts of 63 articles: HTML format

Single Articles

February 2021
1. ANDERSSON E, Ambikan A, Brannstrom J, Aralaguppe SG, et al
   High-throughput sequencing reveals a high prevalence of pretreatment HIV-1 drug resistance in Sweden.
   AIDS. 2021;35:227-234.
   PubMed     Abstract available
   
   
   December 2020
2. MONACO DC, Zapata L, Hunter E, Salomon H, et al
   Resistance profile of HIV-1 quasispecies in patients under treatment failure using single molecule, real-time sequencing.
   AIDS. 2020;34:2201-2210.
   PubMed     Abstract available
   
   
   November 2020
3. MUCCINI C, Spagnuolo V, Canetti D, Bigoloni A, et al
   Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance.
   AIDS. 2020;34:2152-2155.
   PubMed    
   
   
   October 2020
4. BAJEMA KL, Nance RM, Delaney JAC, Eaton E, et al
   Significant decline in heavily treatment experienced persons with HIV with limited antiretroviral treatment options in the US, 2000-2017.
   AIDS. 2020 Oct 12. doi: 10.1097/QAD.0000000000002679.
   PubMed     Abstract available
   
   
   
5. BENNETT SJ, Chunda-Liyoka C, Poppe LK, Meinders K, et al
   High nonnucleoside reverse transcriptase inhibitor resistance levels in HIV-1-infected Zambian mother-infant pairs.
   AIDS. 2020;34:1833-1842.
   PubMed     Abstract available
   
   
   September 2020
6. YOTSUMOTO M, Hachiya A, Ichiki A, Amano K, et al
   Second-generation integrase strand inhibitors can be effective against elvitegravir-derived multiple integrase gene substitutions.
   AIDS. 2020 Sep 14. doi: 10.1097/QAD.0000000000002688.
   PubMed    
   
   
   August 2020
7. GAY CL, Neo DT, Devanathan AS, Kuruc JD, et al
   Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection.
   AIDS. 2020 Aug 7. doi: 10.1097/QAD.0000000000002652.
   PubMed     Abstract available
   
   
   
8. INZAULE SC, Bertagnolio S, Kityo CM, Siwale M, et al
   The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa.
   AIDS. 2020;34:1559-1566.
   PubMed     Abstract available
   
   
   July 2020
9. GIATSOU E, Abdi B, Plu I, Desire N, et al
   Ultradeep sequencing reveals HIV-1 diversity and resistance compartmentalization during HIV-encephalopathy.
   AIDS. 2020 Jul 21. doi: 10.1097/QAD.0000000000002616.
   PubMed     Abstract available
   
   
   
10. INZAULE SC, Jordan MR, Cournil A, Giron-Callejas A, et al
    Tenofovir resistance in early and long-term treated patients on first-line antiretroviral therapy in eight low- and middle-income countries.
    AIDS. 2020 Jul 17. doi: 10.1097/QAD.0000000000002623.
    PubMed     Abstract available
    
    
    May 2020
11. INZAULE SC, Jordan MR, Bello G, Wadonda-Kabondo N, et al
    High levels of resistance to nucleoside/nucleotide reverse transcriptase inhibitors in newly-diagnosed antiretroviral treatment naive children in sub-Saharan Africa.
    AIDS. 2020 May 20. doi: 10.1097/QAD.0000000000002580.
    PubMed     Abstract available
    
    
    March 2020
12. PANPRADIST N, Beck IA, Ruth PS, Avila-Rios S, et al
    Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.
    AIDS. 2020 Mar 19. doi: 10.1097/QAD.0000000000002524.
    PubMed     Abstract available
    
    
    
13. JAMES CW, Szabo S, Kahal D, Goldstein ND, et al
    The effect of multivitamins and polyvalent cations on virologic suppression with integrase strand transfer inhibitors.
    AIDS. 2020;34:487-489.
    PubMed    
    
    
    December 2019
14. YE J, Hao M, Xing H, Zhang F, et al
    Transmitted HIV drug resistance among individuals with newly diagnosed HIV infection: A multicenter observational study.
    AIDS. 2019 Dec 27. doi: 10.1097/QAD.0000000000002468.
    PubMed     Abstract available
    
    
    
15. SALOU M, Butel C, Comlan AS, Konou AA, et al
    Challenges of scale-up to Dolutegravir based regimens in sub-Saharan Africa: a case study in Togo.
    AIDS. 2019 Dec 27. doi: 10.1097/QAD.0000000000002470.
    PubMed     Abstract available
    
    
    November 2019
16. MORANGUINHO I, Borrego P, Goncalves F, Gomes P, et al
    Genotypic resistance profiles of HIV-2 infected patients from Cape Verde failing first-line antiretroviral therapy.
    AIDS. 2019 Nov 14. doi: 10.1097/QAD.0000000000002431.
    PubMed     Abstract available
    
    
    October 2019
17. FOGEL JM, Sivay MV, Cummings V, Wilson EA, et al
    HIV drug resistance in a cohort of HIV-infected men who have sex with men in the United States.
    AIDS. 2019 Oct 10. doi: 10.1097/QAD.0000000000002394.
    PubMed     Abstract available
    
    
    
18. LIU L, Dai L, Yao J, Pan P, et al
    Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naive individuals in a tertiary care hospital in Beijing, China.
    AIDS. 2019;33:1945-1947.
    PubMed     Abstract available
    
    
    September 2019
19. KOUAMOU V, Manasa J, Katzenstein D, McGregor AM, et al
    Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
    AIDS. 2019;33:1729-1737.
    PubMed     Abstract available
    
    
    May 2019
20. INZAULE SC, Mr J, Cournil A, Vitoria M, et al
    Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age: a double setback.
    AIDS. 2019 May 29. doi: 10.1097/QAD.0000000000002277.
    PubMed     Abstract available
    
    
    
21. AMBROSIONI J, Rico JAF, Nicolas D, Mosquera MM, et al
    E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection.
    AIDS. 2019 May 6. doi: 10.1097/QAD.0000000000002243.
    PubMed     Abstract available
    
    
    
22. MOYO S, Gaseitsiwe S, Zahralban-Steele M, Maruapula D, et al
    Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
    AIDS. 2019;33:1073-1082.
    PubMed     Abstract available
    
    
    
23. MILNE RS, Silverman RA, Beck IA, Mckernan-Mullin J, et al
    Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women.
    AIDS. 2019;33:941-951.
    PubMed     Abstract available
    
    
    April 2019
24. ALESSANDRI-GRADT E, Unal G, Leoz M, Plantier JC, et al
    Virological response to INSTI-based antiretroviral combinations in HIV-1 group O infected patients.
    AIDS. 2019 Apr 3. doi: 10.1097/QAD.0000000000002215.
    PubMed     Abstract available
    
    
    December 2018
25. TODESCO E, Wirden M, Calin R, Simon A, et al
    Caution is needed in interpreting HIV transmission chains by ultra-deep sequencing.
    AIDS. 2018 Dec 21. doi: 10.1097/QAD.0000000000002105.
    PubMed     Abstract available
    
    
    October 2018
26. ZUCKERMAN NS, Mor Z, Bucris E, Wax M, et al
    Sexual intermingling of arab and jewish men who have sex with men in israel: results of a molecular epidemiology study.
    AIDS. 2018 Oct 15. doi: 10.1097/QAD.0000000000002057.
    PubMed     Abstract available
    
    
    
27. SCHULTZE A, Torti C, Cozzi-Lepri A, Vandamme AM, et al
    The effect of primary drug resistance on CD4 cell decline and the viral load set-point in HIV positive individuals before the start of antiretroviral therapy.
    AIDS. 2018 Oct 15. doi: 10.1097/QAD.0000000000002046.
    PubMed     Abstract available
    
    
    September 2018
28. KENYON C
    We need to consider collateral damage to resistomes when we decide how frequently to screen for chlamydia/gonorrhoea in PrEP cohorts.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002020.
    PubMed     Abstract available
    
    
    August 2018
29. DAVY-MENDEZ T, Eron JJ, Brunet L, Zakharova O, et al
    New antiretroviral agent use affects prevalence of HIV drug resistance in clinical care populations.
    AIDS. 2018 Aug 20. doi: 10.1097/QAD.0000000000001990.
    PubMed     Abstract available
    
    
    
30. KANTOR R, Delong A, Schreier L, Reitsma M, et al
    HIV Second-Line Failure and Drug Resistance at High- and Low-Level Viremia in Western Kenya.
    AIDS. 2018 Aug 20. doi: 10.1097/QAD.0000000000001964.
    PubMed     Abstract available
    
    
    
31. DELAUGERRE C, Rodriguez C, Capitant C, Nere ML, et al
    Drug resistance among patients who acquired HIV infection in a PrEP trial.
    AIDS. 2018 Aug 8. doi: 10.1097/QAD.0000000000001960.
    PubMed     Abstract available
    
    
    
32. ZHANG X, Ding X, Zhu Y, Chong H, et al
    Structural and functional characterization of HIV-1 cell fusion inhibitor T20.
    AIDS. 2018 Aug 8. doi: 10.1097/QAD.0000000000001979.
    PubMed     Abstract available
    
    
    July 2018
33. DUARTE HA, Beck IA, Levine M, Kiptinness C, et al
    Implementation of a point mutation assay for HIV drug resistance testing in Kenya: performance, challenges, and cost.
    AIDS. 2018 Jul 12. doi: 10.1097/QAD.0000000000001934.
    PubMed     Abstract available
    
    
    June 2018
34. GRAYHACK C, Sheth A, Kirby O, Davis J, et al
    Evaluating outcomes of mother-infants pairs using dolutegravir for HIV treatment during pregnancy.
    AIDS. 2018 Jun 25. doi: 10.1097/QAD.0000000000001931.
    PubMed     Abstract available
    
    
    
35. LOUREIRO RV, Costa MN, Germano I, Calinas F, et al
    Pseudoresistance of hepatitis B virus to tenofovir with emtricitabine.
    AIDS. 2018;32:1387-1388.
    PubMed    
    
    
    
36. ZHANG Y, Fogel JM, Guo X, Clarke W, et al
    Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-Saharan Africa.
    AIDS. 2018;32:1301-1306.
    PubMed     Abstract available
    
    
    
37. OSMAN N, Mesplede T, Oliveira M, Hassounah S, et al
    Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    AIDS. 2018 Jun 11. doi: 10.1097/QAD.0000000000001903.
    PubMed     Abstract available
    
    
    
38. SEATLA KK, Avalos A, Moyo S, Mine M, et al
    Four class drug resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir based antiretroviral therapy in Botswana.
    AIDS. 2018 Jun 11. doi: 10.1097/QAD.0000000000001920.
    PubMed     Abstract available
    
    
    May 2018
39. WOODSON E, Goldberg A, Michelo C, Basu D, et al
    HIV transmission in Discordant Couples in Africa in the context of ART availability.
    AIDS. 2018 May 11. doi: 10.1097/QAD.0000000000001871.
    PubMed     Abstract available
    
    
    April 2018
40. THADEN JT, Gandhi M, Okochi H, Hurt CB, et al
    Seroconversion on PrEP: a case report with segmental hair analysis for timed adherence determination.
    AIDS. 2018 Apr 19. doi: 10.1097/QAD.0000000000001825.
    PubMed     Abstract available
    
    
    February 2018
41. RIPAMONTI D, Zazzi M
    Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from the MODIBIP study.
    AIDS. 2018 Feb 8. doi: 10.1097/QAD.0000000000001776.
    PubMed    
    
    
    January 2018
42. ANDERSSON E, Nordquist A, Esbjornsson J, Flamholc L, et al
    Increase in transmitted drug resistance in migrants from Sub Saharan Africa diagnosed with HIV-1 in Sweden.
    AIDS. 2018 Jan 24. doi: 10.1097/QAD.0000000000001763.
    PubMed     Abstract available
    
    
    December 2017
43. NEOGI U, Singh K, Aralaguppe SG, Rogers LC, et al
    Ex vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV-1 non-B subtypes.
    AIDS. 2017 Dec 12. doi: 10.1097/QAD.0000000000001726.
    PubMed     Abstract available
    
    
    November 2017
44. LODI S, Gunthard HF, Dunn D, Garcia F, et al
    Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance.
    AIDS. 2017 Nov 10. doi: 10.1097/QAD.0000000000001692.
    PubMed     Abstract available
    
    
    
45. INZAULE SC, Hamers RL, Calis J, Boerma R, et al
    When prevention of mother-to-child HIV transmission fails: preventing pretreatment drug resistance in African children.
    AIDS. 2017 Nov 10. doi: 10.1097/QAD.0000000000001696.
    PubMed     Abstract available
    
    
    
46. OLSON A, Bannert N, Sonnerborg A, de Mendoza C, et al
    Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001689.
    PubMed     Abstract available
    
    
    October 2017
47. MENZA TW, Billock R, Samoff E, Eron JJ, et al
    Pretreatment integrase strand transfer inhibitor resistance in North Carolina from 2010-2016.
    AIDS. 2017;31:2235-2244.
    PubMed     Abstract available
    
    
    
48. TARTAGLIA A, Ferrara SM, Sica S, Santantonio T, et al
    Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
    AIDS. 2017;31:2314-2315.
    PubMed    
    
    
    August 2017
49. POPPE LK, Chunda-Liyoka C, Kwon EH, Gondwe C, et al
    HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens.
    AIDS. 2017;31:1885-1889.
    PubMed     Abstract available
    
    
    June 2017
50. GATANAGA H, Brumme ZL, Adland E, Reyes-Teran G, et al
    Potential for immune-driven viral polymorphisms to compromise antiretroviral-based pre-exposure prophylaxis for prevention of HIV-1 infection.
    AIDS. 2017 Jun 23. doi: 10.1097/QAD.0000000000001575.
    PubMed     Abstract available
    
    
    April 2017
51. INZAULE SC, Hamers RL, Mukui I, Were K, et al
    Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya.
    AIDS. 2017 Apr 10. doi: 10.1097/QAD.0000000000001500.
    PubMed     Abstract available
    
    
    
52. LEPIK KJ, Harrigan PR, Yip B, Wang L, et al
    Emergent drug resistance with integrase strand transfer inhibitor-based regimens: Incidence and risk factors.
    AIDS. 2017 Apr 3. doi: 10.1097/QAD.0000000000001494.
    PubMed     Abstract available
    
    
    March 2017
53. KANTHULA R, Rossouw T, Feucht UD, Van Dyk G, et al
    Persistence of HIV-drug-resistance among South African Children given Nevirapine to Prevent Mother-to-Child-Transmission.
    AIDS. 2017 Mar 15. doi: 10.1097/QAD.0000000000001446.
    PubMed     Abstract available
    
    
    January 2017
54. NEWSUM AM, Ho CK, Lieveld FI, van de Laar TJ, et al
    The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
    AIDS. 2017;31:105-112.
    PubMed     Abstract available
    
    
    November 2016
55. KUNKEL A, Crawford FW, Shepherd J, Cohen T, et al
    Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.
    AIDS. 2016;30:2715-2723.
    PubMed     Abstract available
    
    
    
56. BRENNER B, Wainberg MA
    We need to use the best antiretroviral drugs worldwide to prevent HIV drug resistance.
    AIDS. 2016;30:2725-2727.
    PubMed    
    
    
    September 2016
57. MURI L, Gamell A, Ntamatungiro AJ, Glass TR, et al
    Development of HIV drug resistance and therapeutic failure in children and adolescents in rural tanzania - an emerging public health concern.
    AIDS. 2016.
    PubMed     Abstract available
    
    
    
58. VILLABONA-ARENAS CJ, Vidal N, Guichet E, Serrano L, et al
    In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa.
    AIDS. 2016.
    PubMed     Abstract available
    
    
    June 2016
59. OLIVEIRA M, Ibanescu RI, Pham HT, Brenner B, et al
    The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.
    AIDS. 2016.
    PubMed     Abstract available
    
    
    
60. HARPER K
    The emergence of acquired HIV-1 drug resistance has almost been stopped in Switzerland.
    AIDS. 2016.
    PubMed    
    
    
    
61. DUARTE F, Miranda AC, Peres S, Diogo I, et al
    Transmitted drug resistance in drug-naive HIV-2 infected patients.
    AIDS. 2016;30:1687-8.
    PubMed    
    
    
    April 2016
62. MUSIIME V, Kasirye P, Naidoo-James B, Nahirya-Ntege P, et al
    Once versus twice daily abacavir and lamivudine in African children: The randomised controlled ARROW Trial.
    AIDS. 2016.
    PubMed     Abstract available
    
    
    
63. CHUNG MH, Silverman R, Beck IA, Yatich N, et al
    Increasing HIV-1 pre-treatment drug resistance among antiretroviral-naive adults initiating treatment between 2006 and 2014 in Nairobi, Kenya.
    AIDS. 2016.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Drug Resistance is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: